Fulgent Genetics Inc (FLGT) Stock Price, Quote & News

Company Profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 626 350 0537

Fax: 626 454 1667

Website: www.fulgentgenetics.com

Address:

4399 Santa Anita Avenue, El Monte, United States

Chrissixdd Apr. 25 at 1:18 PM

$HIMS looking stretched on valuation vs its industry. cheaper naes in the same space: $FLGT $CNC $UHS $LMRI

0 · Reply

jf152 Apr. 23 at 2:43 PM

$FLGT clearly good results.

0 · Reply

Endergast07 Apr. 22 at 8:23 PM

$FLGT https://ir.fulgentgenetics.com/news-releases/news-release-details/fulgent-selected-present-rapid-oral-abstract-within-head-and

0 · Reply

Sexydream Apr. 22 at 8:18 AM

$FLGT the only way this stock goes back above 20 is if they miraculously have an amazing cancer drug clinical results. Thru "organic" growth in the genetic testing sector this will never escape the teens. Whether you like it or not, it is the fact.

1 · Reply

OfficialStocktwitsUser Apr. 13 at 5:44 PM

$FLGT RSI: 39.76, MACD: -0.7789 Vol: 0.65, MA20: 15.77, MA50: 18.58 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Messerschmittbf109 Apr. 11 at 5:38 AM

$FLGT need to rebreak 15,55 I ‘ll buy only there A bet

1 · Reply

joe77w Apr. 11 at 5:33 AM

$FLGT It should be trading North of 30 usd but pps below 15 USD 😐

0 · Reply

Sexydream Apr. 8 at 5:59 PM

$FLGT I'm out. Bought at 15, out at 16.30. This stock is donezo. Clearly there are serious underlying issues with the company that we don't know about. No stock trades at half cash value with no debt plus values revenue generating business at 0. Just doesn't happen folks. My advice is get out and invest into plenty of beaten down high quality companies. You will be holding this for 10 yrs with no gain.

1 · Reply

TechridyStocks Apr. 3 at 11:12 PM

$FLGT .47 book value 👀👀 I’m in now.

0 · Reply

Sexydream Apr. 2 at 5:42 AM

$FLGT realistically, what's everyone's sell target price? I think if it hits 30 I'm out.

1 · Reply

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

Apr 17, 2026, 3:20 PM EDT - 7 days ago

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Apr 16, 2026, 7:30 AM EDT - 9 days ago

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Mar 17, 2026, 4:31 PM EDT - 5 weeks ago

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Mar 13, 2026, 9:00 AM EDT - 6 weeks ago

Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm

Feb 27, 2026, 7:00 AM EST - 2 months ago

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 7:30 AM EST - 2 months ago

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

Dec 22, 2025, 4:10 PM EST - 4 months ago

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

Nov 7, 2025, 4:05 PM EST - 6 months ago

Fulgent to Participate in Upcoming Conferences

Nov 7, 2025, 7:05 AM EST - 6 months ago

Fulgent Reports Third Quarter 2025 Financial Results

Oct 20, 2025, 6:00 AM EDT - 6 months ago

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025

Aug 1, 2025, 7:00 AM EDT - 9 months ago

Fulgent Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

Jul 10, 2025, 4:05 PM EDT - 10 months ago

Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

Jun 10, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out

Jun 9, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 11 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 6, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect

Jun 4, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation

Jun 3, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 11 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect

May 29, 2025, 10:00 AM EDT - 11 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation

May 24, 2025, 9:19 PM EDT - 11 months ago

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 8:11 AM EDT - 1 year ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

May 2, 2025, 7:00 AM EDT - 1 year ago

Fulgent Reports First Quarter 2025 Financial Results

Apr 10, 2025, 4:05 PM EDT - 1 year ago

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Feb 28, 2025, 7:00 AM EST - 1 year ago

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 4:05 PM EST - 1 year ago

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Feb 4, 2025, 4:00 PM EST - 1 year ago

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Nov 8, 2024, 7:00 AM EST - 1 year ago

Fulgent Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Fulgent Reports Second Quarter 2024 Financial Results

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Jun 10, 2024, 1:00 AM EDT - 2 years ago

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

NEO

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

May 24, 2024, 8:00 AM EDT - 2 years ago

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Chrissixdd Apr. 25 at 1:18 PM

$HIMS looking stretched on valuation vs its industry. cheaper naes in the same space: $FLGT $CNC $UHS $LMRI

0 · Reply

jf152 Apr. 23 at 2:43 PM

$FLGT clearly good results.

0 · Reply

Endergast07 Apr. 22 at 8:23 PM

$FLGT https://ir.fulgentgenetics.com/news-releases/news-release-details/fulgent-selected-present-rapid-oral-abstract-within-head-and

0 · Reply

Sexydream Apr. 22 at 8:18 AM

1 · Reply

OfficialStocktwitsUser Apr. 13 at 5:44 PM

0 · Reply

Messerschmittbf109 Apr. 11 at 5:38 AM

$FLGT need to rebreak 15,55 I ‘ll buy only there A bet

1 · Reply

joe77w Apr. 11 at 5:33 AM

$FLGT It should be trading North of 30 usd but pps below 15 USD 😐

0 · Reply

Sexydream Apr. 8 at 5:59 PM

1 · Reply

TechridyStocks Apr. 3 at 11:12 PM

$FLGT .47 book value 👀👀 I’m in now.

0 · Reply

Sexydream Apr. 2 at 5:42 AM

$FLGT realistically, what's everyone's sell target price? I think if it hits 30 I'm out.

1 · Reply

Endergast07 Apr. 1 at 1:30 AM

$FLGT Around 2 MIO shares bought back by FLGT in the first quarter, if I read a sec filing correctly

0 · Reply

boredmember Mar. 24 at 3:29 PM

$FLGT extremely strong on this down day

0 · Reply

jf152 Mar. 24 at 2:38 PM

$FLGT Good read here: https://seekingalpha.com/article/4881551-fulgent-genetics-a-major-market-misconception

0 · Reply

jf152 Mar. 23 at 10:25 PM

$FLGT it looks like the shorts were hoping the acquisition were be in quarter 2 and they would have another three months of easy manipulation. Screw them. They are evil anyway.

0 · Reply

prismmarketview Mar. 18 at 2:14 PM

Fulgent Genetics (NASDAQ: $FLGT) has closed its roughly $57M “dual” deal to buy Bako Diagnostics assets and all of StrataDx, doubling its pathology sales force and expanding into podiatry and dermatopathology as it builds a nationwide AI‑enabled diagnostic lab platform. https://prismmarketview.com/fulgent-genetics-closes-dual-pathology-deal/

0 · Reply

Endergast07 Mar. 17 at 10:25 PM

$FLGT Still a lot of volume, so many days after earnings, interesting...

1 · Reply

boredmember Mar. 17 at 2:19 PM

$FLGT near term easy $20-22

0 · Reply

BenGang Mar. 13 at 4:42 PM

$FLGT reversal perhaps? Watching it

0 · Reply

Endergast07 Mar. 11 at 10:28 PM

$FLGT Read the latest SEC form 4 to know who is loading up :)

1 · Reply

Messerschmittbf109 Mar. 10 at 7:25 PM

$FLGT one hour ago — Raising target price to $18.00. FULGENT GENETICS INC has an Investment Rating of HOLD; a target price of $18.000000

0 · Reply

Messerschmittbf109 Mar. 10 at 6:23 PM

$FLGT new TP 18-24$ but no rebound yet Funck

0 · Reply

Messerschmittbf109 Mar. 10 at 4:18 PM

$FLGT third attempts to break 15,5 Wait

0 · Reply

Market Cap	476.84M
Revenue (ttm)	322.67M
Net Income (ttm)	-60.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.75%
Debt to Equity Ratio	0.00

Volume	277,400
Avg Vol	628,392
Day's Range	N/A - N/A
Shares Out	29.75M
Stochastic %K	82%
Beta	0.89
Analysts	Sell
Price Target	$26.00